News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SOTIO a.s. Appoints Chiltern International Ltd.



3/18/2013 1:18:46 PM

London, UK, and Wilmington, NC, US, March 18, 2013: Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that SOTIO a.s. has selected Chiltern International Limited to be the CRO that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.

Under the agreement signed in December 2012, Chiltern will be responsible for providing full-service management of the VIABLE phase III clinical trial in Europe. It will be the contracting party for 126 treatment centers in 17 European countries where a total of 750 patients are expected to participate in the trial. Chiltern will also be responsible for processing the data obtained during this clinical evaluation.

Dr Jim Esinhart, CEO, Chiltern, commented, “I am very pleased that we have been selected to manage this high profile trial. I believe it underscores the strengths and expertise of our global Oncology Therapeutic Area Team. We look forward to working in close partnership with SOTIO a.s. to deliver a quality outcome.”

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,500 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com

About SOTIO a.s.

Based in Czech Republic, SOTIO is a biotechnology company that is developing next generation Best-in-Class Active Cellular Immunotherapy (“ACI”), focusing on the treatment of cancer and autoimmune diseases. The company is in the process of developing new medical therapies using an immunotherapy platform based on activated dendritic cells with the view to significantly improving these treatments and making them available to patients. Further information is available at: www.sotio.com

Please contact:

Natalie Chong, Marketing Director

Chiltern International Ltd.

171 Bath Road 1

Slough, Berkshire SL1 4AA, UK

Tel: +44 (0) 1753 512 000

natalie.chong@chiltern.com

Susan Ojanen, Marketing Executive

Chiltern International Inc.

241 Volunteer Parkway, Suite 950

Bristol, TN 37620, USA

Tel: +1 (423) 968 9533

susan.ojanen@chiltern.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES